Crescent Biopharma, Inc. announced its financial results for the quarter ended June 30, 2026, on July 30, 2026. The biopharmaceutical company disclosed operational and financial metrics for the second quarter through a formal disclosure filed with the Securities and Exchange Commission. The announcement comes as the company continues to develop its pipeline of therapeutic programs.

Key Points

  • NASDAQ: CBIO
  • Crescent Biopharma announced second quarter 2026 results on July 30, 2026
  • The company reported results for the period ended June 30, 2026
  • Investors can review the full press release and accompanying disclosures for detailed financial metrics

Quarterly Announcement Released

Crescent Biopharma disclosed its second quarter financial results through a press release issued on July 30, 2026. The announcement provides investors with operational and financial information for the three-month period ended June 30, 2026. The company filed the disclosure in accordance with SEC reporting requirements, furnishing the press release as an exhibit to its current report. This quarterly announcement represents standard financial reporting by the biopharmaceutical company to keep shareholders informed of its operational status and financial position during the period.

Company Background and Market Position

Crescent Biopharma, Inc. is a biopharmaceutical company incorporated in the Cayman Islands and trading on the Nasdaq Capital Market under the ticker symbol CBIO. The company is headquartered in Waltham, Massachusetts, with its principal executive offices located at 300 Fifth Avenue. As a publicly traded biopharmaceutical entity, Crescent Biopharma operates within the regulated pharmaceutical and biotechnology sector, subject to SEC oversight and disclosure obligations. The company's ordinary shares carry a par value of $0.001 per share.

Disclosure Details and Investor Access

The detailed financial results, including specific operational metrics and financial figures for the second quarter, were contained in the press release furnished by the company. The disclosure was filed as a current report and the press release was attached as an exhibit to the regulatory filing. Investors seeking comprehensive financial information about Crescent Biopharma's second quarter performance can access the full press release through the SEC's EDGAR database or the company's investor relations channels. The announcement provides the formal quarterly update required to maintain transparency with shareholders and the investment community.